MedTrace Logo

A Clinical Evaluation of the Aliya™ System in Late Stage Cancer

NCT04773275 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2025-08-01

No results posted yet for this study

Summary

A prospective, single-arm, non-randomized, multi-center, open-label study following patients to 1 year. The study is designed to evaluate the safety and clinical utility of Pulsed Electric Field (PEF) treatment of advanced stage or metastatic cancer following progression on immunotherapy.

Conditions

  • Cancer of Lung, Kidney or Liver

Interventions

DEVICE

Pulsed electric field treatment using the Aliya system

Patients will undergo pulsed electric field (PEF) treatment of up to 5 tumors (new or progressing) measuring ≤ 2cm in longest diameter.

Sponsors & Collaborators

  • Galvanize Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-09
Primary Completion
2023-02-23
Completion
2023-04-21
FDA Device
Yes

Countries

  • Hong Kong
  • Netherlands
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04773275 on ClinicalTrials.gov